Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have earned an average recommendation of “Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.00.
Several research firms recently commented on PIRS. ValuEngine raised Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Cowen reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, May 13th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pieris Pharmaceuticals in a research report on Thursday, August 1st. William Blair reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Friday, August 16th. Finally, Zacks Investment Research raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday.
Shares of Pieris Pharmaceuticals stock traded down $0.03 during trading on Wednesday, hitting $4.77. 12,798 shares of the company’s stock traded hands, compared to its average volume of 803,661. Pieris Pharmaceuticals has a 1 year low of $2.39 and a 1 year high of $6.04. The stock has a market capitalization of $233.62 million, a P/E ratio of -9.54 and a beta of 1.26. The business has a 50-day simple moving average of $4.84 and a 200-day simple moving average of $3.83.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.